Field Report: Discover pragmatic examples of customer benefits
Niger: the future of nomad populations into question
![Rapport environnemental social et sociétal de COMURHEX Malvési 2010 [FR]](/mediatheque/liblocal/images/mediatheque/vignettes/activites/amont/chimie/vignette-Malvesi-2010.png)
Rapport environnemental social et sociétal de COMURHEX Malvési 2010 [FR]
AREVA funds new infrastructures for Arlit (Niger)
Building of a public library in Arlit (Niger)
Youth professional training programs: Agapè (Niger)
"Comurhex II" brochure
Scolarships for 60 engineers and technicians in Niger
Three AREVA employees working with Planète Urgence
Setting up a micro-credit agency in Arlit (Niger)
France: Institut Pasteur - 2009
Research on patients who have been HIV positive since birth
Already working alongside the Institut Pasteur in Shanghai on the issue of climate change and its impact on viral and emerging diseases, the AREVA Foundation also wanted to support the Institut Pasteur in Paris.
The Institut Pasteur
The Institut Pasteur is a renowned private foundation recognized for its contribution to the public good. Its mission is to prevent and fight disease, in France and around the world, through scientific and medical research, education and public health services.
Targeted research
The AREVA Foundation is committed to supporting the work of Florence Buseyne, Head of Research in the Viral Immunopathology Unit, on treating patients who have been HIV positive since birth.
Today, in developed countries, children infected at birth are reaching adulthood. In France, a quarter of these patients are monitored by adult medical services, which fails to take into account whether adults infected since birth should be treated like other patients. There are many differences between infection at birth and infection during adulthood (clinical development, level of viral infection, maturity of the immune system, etc.).
This project involves conducting a detailed study of the immune system and analyzing 200 subjects who have been infected with AIDS for at least 15 years in order to:
- improve long-term therapeutic care for patients who have been infected since birth,
- better understand the disease.
